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Abstract 
Background: Periodontitis is one of major oral diseases, which has no consensus on early screening tool. This study 
aimed to compare the association and screening ability of S100A8 and S100A9 in saliva, blood and gingival crevicular 
fluid (GCF) for periodontitis status.
Methods: We recruited 149 community Korean adults, 50 no or initial periodontitis (NIPERIO) and 99 established 
periodontitis (PERIO). Using clinical attachment loss and a panoramic radiograph, stage II–IV of new classification of 
periodontitis proposed at 2018 was considered cases as PERIO. Enzyme linked immunosorbent assay kit was used to 
quantify S100A8 and S100A9. T‑test, analysis of covariance, Mann–Whitney test and correlation analysis were applied 
to compare the relationship of S100A8 and S100A9 in saliva, blood, and GCF for periodontitis. Receiver operating 
characteristic curve was applied for screening ability.
Results: Among S100A8 and S100A9 in saliva, blood and GCF, S100A8 in saliva was significantly higher in PERIO than 
in NIPERIO (p < 0.05). However, S100A8 and S100A9 in GCF were higher in NIPERIO (p < 0.05). The screening ability of 
salivary S100A8 was 75% for PERIO, while that of GCF S100A8 was 74% for NIPERIO. Salivary S100A8 was positively cor‑
related to blood S100A8 (p < 0.05).
Conclusion: Salivary S100A8 could be a potential diagnostic marker for established periodontitis and be useful for 
screening established periodontitis.
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Background
Periodontitis, the major oral disease, is a polymicrobial 
infectious disease that is related with systemic inflam-
mation, destroys supporting tissue around the tooth and 
ultimately leads to tooth loss [1, 2]. Systematic disease 
like diabetes, cardiovascular and stroke has been shown 
to be associated with periodontitis [3–5]. Polymicrobial 
biofilm interacts with periodontal tissue and the biofilm 
triggers the host response, which leads to elevate sys-
temic inflammation through change in proteins, immu-
noglobulins and inflammatory mediators [6, 7]. Upon 
activation of inflammatory mediators, various degra-
dation pathways are activated that causes secretion of 
destructive cellular molecules like protease, reactive oxy-
gen species, chemokines and cytokines [8].
Early detection of periodontitis is necessary for pub-
lic health in a preventive dimension, because it leads to 
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tooth mobility, tooth loss, mastication deficiencies and 
digestive problems [9]. Periodontitis is conventionally 
identified by dentist, inspecting the tissues around the 
teeth and using radiograph to determine bone loose 
around the teeth. However, the clinical procedures of 
present diagnostic measures are time consuming and 
too delayed to be restored.
Biofluids like blood, saliva, urine, tears have been 
used as source of biomarkers for certain disease [10]. 
Scientists are focusing much attention on biofluids, 
compared to use of tissue because of several factors 
like ease of accessibility, low cost of obtainment, avoid-
ing risk of biopsies, and availability of multiple sam-
pling [11]. Saliva contains proteins, peptides, organic 
and inorganic salts, electrolytes from blood with addi-
tional contribution from mucosal transudates and 
gingival crevicular fluid (GCF) [12]. Therefore, saliva 
has been studied and used for diagnostic tools over 
last decade. Recently salivary biomarkers have been 
applied for cardiovascular disease, autoimmune dis-
eases, diabetes, HIV, oral cancer, caries and periodon-
tal diseases [13].
S100A8 and S100A9 are a subgroup of molecules 
within the broader family of S100 calcium-binding 
protein and it has ability to bind with zinc. These pro-
teins are mostly expressed on neutrophils and mono-
cytes or macrophages [14]. Previously it has been 
reported that increased concentration of S100A8/A9 
in saliva and serum were associated with periodonti-
tis patients [15, 16]. Similarly, GCF fluid containing 
S100A8 and S100A9 was associated with periodontitis 
[17]. Thus salivary S100A8 and S100A9 have been spe-
cific targets for researcher and practitioners who are 
interested to identify periodontitis using robust and 
cost-effective method [18]. One study reported that 
salivary calprotectin (S100A8/9) was compared with 
that in serum, which had only 100 participants [16]. 
There has been no comparative evidence on S100A8 
and S100A9 among saliva, blood and GCF. Hence 
more evidence is needed to compare salivary S100A8 
and S100A9 with those in blood and GCF from more 
sufficient number of participants. Thus, the hypothe-
sis of this study was that S100A8 and S100A9 in saliva, 
blood and GCF show the difference in the association 
and screening ability of S100A8 and S100A9 in saliva, 
blood and GCF according to the periodontitis status.
Hence, the present study aimed to compare the asso-
ciation and screening ability of S100A8 and S100A9 in 
saliva, blood and GCF according to the periodontitis 
status.
Methods
Study design and ethical consideration
This cross-sectional study randomly selected partici-
pants from public advertisement. All of the partici-
pants voluntarily provided a written informed consent. 
The Institutional Review Board for Human Subjects of 
Seoul National University Dental Hospital reviewed 
and granted the ethical consideration for this study 
(CRI17009). This study was organized according to the 
checklist of items included in STROBE (cross-sectional 
studies) (Additional file 1).
Sample size estimation
The results of pilot test using ten participants (each 
five cases and controls) showed that S100A8 in saliva 
[mean ± standard deviation (SD), ng/ml] was 8.0 ± 10.2 
for established periodontitis (PERIO) patients versus 
6.1 ± 8.3 for no or initial periodontitis (NIPERIO) par-
ticipants. Under the condition of type I error of 0.05, 
type II error of 0.8 and ratio of 2 between PERIO and 
NIPERIO participants, the sample size of this study was 
estimated as total of 147 (98 PERIO and 49 NIPERIO). 
Sample size was estimated 18 (12 PERIO and 6 NIPE-
RIO) for S100A8 in GCF (0.4 ± 0.4 for NIPERIO vs. 
0.15 ± 0.3 for PERIO) and 27 (18 PERIO and 9 NIPE-
RIO) for S100A8 in blood (600 ± 240 for PERIO vs. 
490 ± 210 for NIPERIO). The estimated sample size for 
S100A9 was 141 (94 PERIO and 47 NIPERIO) in saliva 
(1.2 ± 1.9 for NIPERIO vs. 1.6 ± 2.1 for PERIO), 21 (14 
PERIO and 7 NIPERIO) in GCF (0.2 ± 0.2 for NIPE-
RIO vs. 0.08 ± 0.2 for PERIO) and 39 (26 PERIO and 13 
NIPERIO) in Blood (159 ± 28 for NIPERIO vs. 170 ± 24 
for PERIO). Finally, we decided the total samples size of 
this study was 147 (98 PERIO and 49 NIPERIO).
Study participants
The total of 149 community Korean adults, 50 no or 
initial periodontitis and 99 established periodontitis 
were recruited. The inclusion criteria for participants of 
this study were five-fold. (1) Those who agreed to take 
periodontal examination including clinical attachment 
loss (CAL) and panoramic radiograph according to the 
new international periodontal classification guideline 
by American Academy of Periodontitis and European 
Federation of Periodontology [19], (2) Those who aged 
over 20 years, (3) Those who had no medication during 
previous three months, (4) Those who agreed to donate 
adequate sample of blood, GCF and saliva for analysis 
(5) Those who had no missing data used in the final 
analysis.
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Assessment of periodontitis
Trained dentists examined CAL and radiographic bone 
loss by using panoramic radiograph (Pax-Primo, Vatech 
Global, Seoul, Korea). CAL was calculated by adding 
up pocket depth and gingival recession using a UNC-
15 probe in all of the natural teeth except 3rd molar. 
Periodontal status was categorised according to the 
guidelines of 2017 American Association of Periodon-
tology—European Federation of Periodontology work-
shop in Periodontology [19]. Among our participants, 
only two participants were periodontally healthy and 48 
participants were classified into Stage I (initial) perio-
dontitis with CAL 1–2 mm and no history of extraction 
due to periodontitis. So, the participants with Stage II–
IV periodontitis were considered as established peri-
odontitis (PERIO) and the other participants with no 
or Stage I periodontitis were no or initial periodontitis 
(NIPERIO). Stage II–IV periodontitis is CAL ≥ 3  mm 
or extraction due to periodontitis or radiological bone 
loss > 15% of coronal third [19].
Assessment of clinical periodontal parameters
Plaque index (PI), pocket depth (PD) and bleeding on 
probing (BOP) were considered as periodontal clinical 
parameters. PI was evaluated by Turesky modification 
of the Quigley–Hein Index [20]. PD was evaluated at six 
sites per tooth (mesio-, mid- and disto-buccal and lin-
gual) using a UNC-15 probe and dichotomized according 
to PD ≥ 4 mm. BOP was evaluated using the guideline in 
a previous study [21]. Finally, PI, PD and BOP were pre-
sented as PI, percentage of site with PD ≥ 4 mm and per-
centage of site with BOP positive.
Saliva sampling
Information about the standard sampling protocol for 
saliva collection was provided to each participant: not 
to brush tooth, not to drink or eat one hour before sam-
pling. In order to maintain consistency of samples, we 
collected unstimulated whole saliva using passive drool-
ing method for 10 min in a 50 ml conical tube. We centri-
fuged the saliva by 2600×g for 15 min at 4 °C, aliquoted 
supernatants into 1 ml in sterilised 1.5 ml Eppendorf tube 
and stored the aliquoted saliva samples in – 80 °C deep-
freezers for further analysis.
GCF collection
Radiographic evaluation and periodontal probing using 
UNC-15 probe were applied to decide the deepest pocket 
among all teeth pockets. GCF samples were obtained 
from the deepest pocket. During GCF sampling, we tried 
to avoid blood and saliva contamination. After isolating 
the tooth with cotton rolls, three absorbent paper points 
(#25, Meta Biomed Inc., Chungbuk, Korea) were gently 
inserted in the same deepest pocket for 30 s. Paper points 
were immediately placed in a cryovial containing 1 ml of 
phosphate buffer saline in pH 7.4, which were centrifuged 
(2600×g for 15  min at 4  °C) and supernatants were ali-
quoted into 1 ml in sterilised 1.5 ml Eppendorf tube. The 
tubes with GCF samples were stored at stored at − 80 °C 
for further analysis.
Blood collection
Blood of 4  ml was drawn by venepuncture by a trained 
medical technologist. The blood samples were centri-
fuged (2600×g for 15  min at 4  °C) and supernatants 
(plasma) were aliquoted into 1  ml in sterilised 1.5  ml 
Eppendorf tube. The tubes were then stored at −  80  °C 
for further analysis.
Quantification of salivary S100A8 and S100A9
S100A8 and S100A9 protein concentrations were deter-
mined from saliva, blood and GCF using enzyme-linked 
immunosorbent assay (ELISA) kit (R&D systems, Min-
neapolis, MN, USA) with validation for cell culture 
supernatant and blood sample through manufacturer’s 
instruction. Standard curve was drawn using stand-
ard S100A8 and S100A9 supplied by the manufacturer. 
GCF and saliva samples were diluted on concentration 
dependent using reagent diluent provided by manufac-
ture (1, 1/2, 1/4, 1/8, 1/16, 1/32) and diluted sample con-
certation for S100A8 and S100A9 were calculated from 
standard curve of S100A8 and S100A9. Similarly, blood 
samples were diluted on concentration dependent man-
ner with reagent diluent (1/10, 1/20, 1/40, 1/80, 1/160, 
1/320) and concentrations of S100A8 and S100A9 were 
estimated using standard curve. We decided the standard 
dilution rate that falls on the range of 500–1000 pg/ml on 
pilot study.
Assessment of confounding variables
We considered sociodemographic factors such as sex 
and education, behavioural factors such as smoking and 
drinking, and systemic health information including obe-
sity, diabetes, hypercholesterolemia and hypertension 
as confounders. Face to face interview, laboratory blood 
analysis and physical examination were applied to col-
lect the data for confounders. We dichotomised following 
variables: education (until middle school vs. above high 
school), smoking (smoker encompassing past and cur-
rent smoker versus non-smoker who has never smoked 
during the lifetime), drinking (alcohol drinker encom-
passing past and current drinker vs. non-drinker who 
has never drunk during the lifetime). We classified four 
systemic health components as follows: (1) obesity: body 
mass index (BMI) calculated as kg of body weight divided 
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by square meter of height ≥ 25, (2) diabetes: high plasma 
glucose level (> 126 g/dl) or having anti-diabetic medica-
tion, (3) hypercholesterolemia: high plasma cholesterol 
level (> 240  mg/dl) or having anti-hypercholesterolemia 
medication, and (4) hypertension: systolic > 130  mmHg 
or diastolic > 85 mmHg or having anti-hypertensive med-
ication. The blood pressure was measured by physicians 
in the sitting position using mercury manometer. We 
assayed biochemical variables using 12-h fasting blood 
samples drawn at recruitment.
Statistical analysis
The distribution of characteristic variables by periodon-
titis status (NIPERIO vs. PERIO) were addressed using 
mean values with standard deviations (SD) for continuous 
variables, and frequencies and proportion for categori-
cal variables. Chi-square test was applied for categorical 
variables. Kolmogorov–Smirnov (K–S) test was applied 
to evaluate the normal distribution for continuous vari-
ables. When variables were in normal distribution, par-
ametric tests were applied, otherwise non-parametric 
tests were applied. T-test were performed to evaluate dif-
ference in continuous variables with normal distribution. 
Mann–Whitney (M–W) test were applied for continuous 
variables without normal distribution. The relationships 
between values in the blood, GCF and saliva were ana-
lysed with Spearman’s correlation test. Since number of 
participants were big (n = 149), Analysis of covariance 
(ANCOVA) was applied to estimate adjusted mean with 
standard error (SE) of S100A8 and S100A9 levels after 
controlling for age, sex, education, smoking, drinking, 
diabetes, hypercholesterolemia, hypertension and obe-
sity. The receiver operating characteristic (ROC) curve 
was applied for estimating c-statistics (area under the 
curve: AUC) as screening ability of S100A8 and S100A9 
for periodontitis status. Statistical significance was set at 
p value < 0.05. Data were analysed using Statistical Pack-




The participants of this study aged from 21 to 77 years. 
The PERIO participants were older, more males, more 
hypertensive and more obese than the NIPERIO par-
ticipants (p < 0.05) (Table  1). The PERIO participants, 
compared to the NIPERIO participants, were higher edu-
cated, more diabetic, more hypercholesterolemia, more 
smokers and drinkers, which were not statistically signifi-
cant (p > 0.05).
The PERIO patients, compare to the NIPERIO par-
ticipants, showed significantly higher values in clinical 
periodontal parameters including PI, PD ≥ 4  mm and 
BOP (T-test, p < 0.05) (Table 1).
S100A8 and S100A9 in saliva, blood, GCF by periodontitis
S100A8 and S100A9 in saliva, blood and GCF were not 
in normal distribution (K–S test, p < 0.05). The repre-
sentative level of S100A8 in saliva was higher in PERIO 
participants than in NIPERIO participants (M–W test, 
p < 0.05) (Fig.  1). Although blood showed no differ-
ence in S100A8 according to periodontitis status, GCF 
showed was lower S100A8 in PERIO participants than 
in NIPERIO participants (M–W test, p < 0.05). How-
ever, S100A9 in GCF was lower in PERIO participants 
than in NIPERIO participants (M–W test, p < 0.05). 
S100A9 in saliva and blood showed no difference.
The adjusted value of S100A8 in saliva, after control-
ling for confounders, was also higher by 1.6 and 1.8 
times in stage II and stage III–IV periodontitis par-
ticipants than in NIPERIO participants (ANCOVA, 
p < 0.05) (Table 2). That of S100A9 in saliva showed no 
difference (ANCOVA, p > 0.05). In blood, the adjusted 
value of S100A8 and S100A9 were not significantly dif-
ferent according to periodontitis status (ANCOVA, 
p > 0.05). However, the adjusted values of S100A8 and 
S100A9 in GCF were higher by around 2.5 times in 
NIPERIO participants than in stage II and stage III–IV 
periodontitis participants (ANCOVA, p < 0.05).
Correlation between S100A8 and S100A9 in saliva, blood, 
GCF
Scatter plot showed that S100A8 in saliva was posi-
tively correlated to that of blood (n = 149, r = 0.21, 
p < 0.05) (Fig.  2). This correlation increased by 50% in 
NIPERIO participants (n = 50, r = 0.32, p < 0.05). How-
ever, S100A9 in saliva was negatively correlated to 
that in GCF among PERIO patients (n = 99, r = −0.20, 
p < 0.05).
Screening ability of S100A8 and S100A9 in saliva, blood, 
GCF for periodontitis
ROC curve showed that salivary S100A8 had high-
est screening ability for PERIO among S100A8 and 
S100A9 in saliva, blood, and GCF (Fig.  3). The screen-
ing ability of salivary S100A8 for PERIO was c-statistics 
of 0.73 (p < 0.05), while that of salivary S100A9 was 0.50 
(p > 0.05). S100A8 and S100A9 in GCF showed high 
screening ability of 0.74 and 0.62 for NIPERIO (c-sta-
tistics of 0.26 in S100A8 and 0.38 in S100A9 for PERIO, 
p < 0.05), respectively. S100A8 and S100A9 in blood 
showed non-significant c-statistics of 0.5 (p > 0.05).
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Discussion
Our data showed that salivary S100A8 had the most 
appropriate screening ability for periodontitis among 
S100A8 and S100A9 in saliva, blood and GCF. To the 
best of our knowledge, this is the first evidence that 
salivary S100A8 could be the best maker for screen-
ing established periodontitis after comparing among 
S100A8 and S100A9 in saliva, blood and GCF. This 
result was supported by the previous evidence that 
salivary S100A8/9, calprotectin, was a significant maker 
for periodontitis [16].
Comparing with the previous study, our study had 
some advantage. Firstly, this study compared S100A8 
and S100 A9 levels among saliva, blood and GCF. Sec-
ondly, sufficient 149 number of participants were ran-
domly recruited from the general population and there 
was no selection bias. Thus, our results could be gener-
alized. Thirdly, age, sex, smoking, drinking, education, 
Table 1 Characteristics of the participants according to periodontitis status (n = 149)
Bold denotes statistical significance at p < 0.05
PERIO stage II–IV periodontitis (AAP-EFP, 2018), NIPERIO No or stage I periodontitis
p values: obtained by chi-square test for categorical variables and T-test for acontinuous variables. SD standard deviation
b Smoking: No = never smoked, Yes = past and current smoker
c Alcohol intake: No = never drunken, Yes = past and current drinker
d Diabetic: Yes = fasting plasma glucose > 126 or taking diabetes medication
e Hypercholesterolemia: Yes = plasma cholesterol > 240 or taking hypercholesterolemia medication
f Hypertension: Yes = systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or taking hypertension medication
g Obesity: Body mass index (body kg/height  m2) ≥ 25
Variable NIPERIO (n = 50) PERIO (n = 99) p value
Clinical parametera, mean ± SD
Plaque index 0.94 ± 0.72 1.26 ± 1.03 0.033
Site with pocket depth ≥ 4 mm (%) 0.24 ± 0.80 14.67 ± 16.02 < 0.001
Bleeding site on probing (%) 60.26 ± 30.22 71.07 ± 25.80 0.025
Agea, mean ± SD 42.1 ± 15.1 55.8 ± 11.6 < 0.001
Sex, n(%) 0.005
Male 15 (30.0) 54 (54.5)
Female 35 (70.0) 45 (45.5)
Education, n(%) 0.054
Middle school 0 (0.00) 7 (7.1)
High school or higher 50 (100.0) 92 (92.9)
Smoking, n(%)b 0.262
No 48 (96.0) 90 (90.9)
Yes 2 (4.0) 9 (9.1)
Drinking, n(%)c 0.326
No 30 (60.0) 51 (51.5)
Yes 20 (40.0) 48 (48.5)
Diabetic, n(%)d 0.269
No 49 (98.0) 93 (93.9)
Yes 1 (2.0) 6 (7.0)
Hypercholesterolemiae, n(%) 0.102
No 49 (98.0) 90 (90.9)
Yes 1 (2.0) 9 (9.1)
Hypertensionf, n (%) 0.005
No 49 (98.0) 81 (81.8)
Yes 1 (2.0) 18 (18.2)
Obesityg, n (%) 0.031
No 40 (80.0) 62(62.6)
Yes 10 (20.0) 37 (37.4)
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diabetic, hypercholesterolemia, hypertension and obe-
sity were considered as confounders for the adjust-
ment. Fourthly, physical and dental examination were 
performed by physicians and trained dentists using 
UNC-15 probes and a panoramic radiograph. Fifthly, 
periodontitis was classified according to the recent 
New international classification of periodontitis [19]. 
Finally, concentrations of S100A8 and S100A9 were 
quantify using ELISA kits at picogram level.
Fig. 1 Distribution of S100A8 (pg/ml) and S100A9 (pg/ml) according to periodontitis status (0[n = 50]: no or stage I; 1[n = 99]: stage II–IV) (n = 149). 
A S100A8 in saliva (p < 0.001), blood (p = 0.621) and gingival crevicular fluid (GCF) (p < 0.001). B S100A9 in saliva (p = 0.976), blood (p = 0.989) and 
GCF (p = 0.013)
Table 2 Differences in adjusted value (mean ± standard error) of S100A8 (pg/ml) and S100A9 (pg/ml) by periodontitis status (n = 149)
Bold denotes statistical significance at p < 0.05
p values: obtained by ANCOVA for adjusted mean and standard error
Values were adjusted for age, sex, education, smoking, drinking, obesity, diabetes, hypercholesterolemia, and hypertension by ANCOVA in GLM. Superscript denotes 
same groups according to Bonferroni’s post hoc multiple comparison test
Protein Periodontitis status p value
Sample No-Stage I (n = 50) Stage II (n = 76) Stage III–IV (n = 23)
S100A8 (pg/ml)
Saliva 5348.53 ± 794.80a 8152.65 ± 607.91b 9512.13 ± 1132.64b 0.007
GCF 416.43 ± 56.02a 146.84 ± 42.85b 187.40 ± 79.84b 0.002
Blood 497,523.22 ± 35,568.06 579,163.20 ± 27,204.67 648,641.67 ± 50,687.01 0.057
S100A9 (pg/ml)
Saliva 1430.58 ± 393.97 1380.99 ± 301.33 1780.66 ± 561.44 0.820
GCF 230.12 ± 36.41a 98.17 ± 27.85b 63.59 ± 51.89b 0.011
Blood 162,405.26 ± 4146.13 172,167.34 ± 3171.22 166,097.21 ± 5908.53 0.189
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Our data showed that elevated levels of S100A8 in 
saliva were significantly associated with PERIO in 
Korean adults. A recent Korea study reported that sali-
vary S100A8 levels were higher by 70% in periodontal 
disease than that of healthy participants [22]. S100A8 
expression is up-regulated by oxidative stress, cytokine 
and growth factors [23] followed by activation of FcγRI 
and FcγRIV on macrophages through TLR-4 [24, 25], 
and enzymes from chondrocytes suggesting a role in 
pericellular matrix degradation [26]. Chinese and Swiss 
Fig. 2 Correlation of salivary S100A8 (pg/ml) and S100A9 (pg/ml) with blood and gingival crevicular fluid (GCF) according to periodontitis status 
(NIPERIO[n = 50]: no or stage I; PERIO[n = 99]: stage II‑IV) (n = 149). A Salivary S100A8. B Salivary S100A9. r: correlation coefficient
Fig. 3 Receiver operating characteristic (ROC) curve for established periodontitis (stage II–IV) screening ability (c‑statistics) of S100A8 and S100A9 
in saliva, blood and gingival crevicular fluid (GCF) (n = 149)
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human studies [17, 27] reported positive results in GCF. 
An English study also showed that S100A8 in GCF was 
significantly higher in inflammatory gingival tissue than 
that of normal tissue [28]. However, our data showed 
that S100A8 in GCF was significantly higher in NIPERIO 
than in PERIO participants. Hence, more study on GCF 
S100A8 should be indicated to make certain the discrep-
ancies of the results.
S100A9 involved in the regulation of inflammatory 
processes and immune response [29]. Calprotectin, 
S100A8/A9, is the marker for gingivitis and periodonti-
tis [30, 31]. Since the main extracellular form of S100A8 
and S100A9 is as a heterodimer (S100A8/A9 or calpro-
tectin), the role of calprotectin should have been consid-
ered. Down regulation of S100A9 protein could indicate 
insufficient immunity stimulated by the infection [32]. 
This protein also promotes apoptosis and modulate the 
inflammatory response in periodontal ligament cells so 
its downregulation could suggest a suppression of inflam-
mation [33, 34]. Antimicrobial activity of S100A9 also 
have been reported. The mechanism behind antimicro-
bial activity is the monomeric form of amyloid beta 1–42 
that is negatively regulated by the innate immune system 
by downregulating the secretion of S100A9 [35]. How-
ever, our data showed that only GCF S100A9 level was 
significantly lower in PERIO than in NIPERIO. Recently, 
a Korean study reported that salivary S100A9 was also 
decreased in periodontitis patients compared to healthy 
participant [22]. However, our S100A9 data did not show 
significant difference in both saliva and blood. Thus, 
more studies are indicated to clarify these discrepancies.
Our data showed that S100A8 in saliva and blood was 
positively correlated each other. This link was higher in 
healthy adults compare to in periodontitis patients. These 
results showed the evidence that saliva represented local 
and systemic inflammation via GCF and blood, while 
blood represented only systemic inflammation. Hence, 
salivary S100A8 showed highest screening ability among 
S100A8 and S100A9 in saliva, GCF and blood. Contrary 
to previous studies [30, 31], salivary S100A9 in our data 
was negatively correlated to that of GCF, especially in 
periodontitis patients. Down regulation of S100A9 pro-
tein could indicate insufficient immunity [32] and could 
be prone to have periodontal inflammation. However, 
further studies are needed to elucidate the mechanism 
of these results. As to established periodontitis, salivary 
S100A8 could be the best consistent biological marker 
among S100A8 and S100A9 in saliva, GCF and blood.
Our data showed that the screening ability of S100A8 
for established periodontitis was 0.73 of c-statistics, 
which was higher than the previous Korean study [22] 
with 0.6 of c-statistics and a bit lower than Austrian 
[16] calprotectin study with 0.86 of c-statistics. Since 
salivary S100A8 could be the best marker for peri-
odontitis, a rapid test kit using salivary S100A8 could 
be effective on promoting periodontal health for gen-
eral public. The next step of Salivary S100A8 research 
should be focused on whether salivary S100A8 could be 
the prognostic marker for periodontitis. The interven-
tion of periodontitis using periodontal treatment will 
elucidate the role of S100A8 on periodontitis prognosis.
There are some limitations of this study. Firstly, sam-
ples were analysed using ELISA were stored more than 
one month. Long term storage of saliva might influence 
on the detection of salivary protein [36]. Secondly, ele-
vated level of S100A8 and S100A9 observed in cancer 
and other inflammatory diseases. This could degrade 
diagnostic ability for periodontitis. Thirdly, the inclu-
sion of a patient with stage I (initial) periodontitis in 
the control group can lead to misinterpretations and 
misclassification bias toward the null. Further studies 
should include only periodontally healthy participants 
in the control group for reducing this type of misclas-
sification bias. Finally, Periapical radiograph is the ideal 
radiograph to assess radiographic periodontal bone loss 
(R-PBL). However, we selected panoramic radiograph 
instead of intraoral radiograph due to the time and 
efforts, because intraoral and panoramic R-PBL meas-
urements have been demonstrated to be clinically coin-
cident [37]. Notwithstanding these limitations, our data 
is appropriate to meet the objectives of this study.
Conclusion
Overall, elevated level of salivary S100A8 protein con-
centration could be a valid marker for established peri-
odontitis screening. Thus, S100A8 salivary kit will be 
useful for screening established periodontitis. Further 
prospective studies including periodontal treatment 
will be indicated for elucidating the prognostic effect 
of salivary S100A8 for the promotion of periodontal 
health.
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